A B S T R AC T
Background. Lupus nephritis (LN) strongly affects the outcome in children with systemic lupus erythematosus (SLE). Many patients, however, have renal disease at onset, but lack a sufficient number of criteria to be diagnosed as SLE and develop delayed symptoms over time (d-SLE). Data on the clinical course, long-term outcome and predictors of disease progression in children with LN are scant. Methods. The Italian Collaborative Study included 161 paediatric patients with LN who were followed up for a mean of 96 months (range 6-296) in seven paediatric nephrology units. Cox-Mantel regression models were used to identify predictors of disease remission, relapse and progression. Results. At 1 year, the proportion of patients in remission was 83.2% ( partial) and 53.5% (complete). Renal flares occurred in >50% of patients within 10 years. The intensity of induction treatment correlated significantly with the achievement of remission, while d-SLE, class IV LN and younger age were associated with poor response to treatment and/or with progression to chronic renal failure. Conclusions. The current study provides outcome data on a large paediatric population with LN and underlines the importance of prescribing appropriate induction treatment to all children, regardless of the presence of enough SLE criteria, which may develop several years after the initial diagnosis.
I N T R O D U C T I O N
Systemic lupus erythematosus (SLE) is a severe disease in paediatric patients; ∼55% of patients have lupus nephritis (LN) at onset [1] .
Currently, the diagnosis of SLE is based on a scoring system developed by the American College of Rheumatology (ACR) [2] . This classification is based on a set of 11 criteria; the diagnosis of SLE is confirmed when at least 4 criteria are present, is likely when 3 criteria are present and is suspected when 2 criteria are present.
Unlike adults, the clinical picture of SLE is often less characteristic in paediatric patients and a significant proportion of children present with severe renal disease at onset [3] , but lack a sufficient number of criteria to be clearly diagnosed as having SLE. When these patients are described in the literature, they are generally referred to as 'full house nephropathy' (FHN), to highlight the immunofluorescence (IF) pattern of their renal lesions, or 'Lupus sine Lupus' or 'Lupus-like nephritis' to highlight the absence or insufficient number of ACR criteria [4] [5] [6] [7] [8] .
Other authors have also classified some of these patients as 'C1q nephropathy', which includes various lesions that share positive C1q staining by IF, but may also have a more rich IF pattern [9] [10] [11] [12] . Over time, many of these patients develop other SLE symptoms and are reclassified as having SLE [13] .
Overall, LN remains a rare disease in children, and very few data are available on the best treatment modality and on the long-term prognosis. In the present work, we report the analysis of an Italian Collaborative Study that has collected 161 patients with LN from 1978 to 2010.
P AT I E N T S A N D M E T H O D S
The present study is a retrospective multicentre analysis of paediatric patients with LN, which was sponsored by the Italian Ministry of Health and approved by the local Institutional Review Board.
Patient selection criteria
All participating centres have reviewed retrospectively their renal biopsies and have included in the study all patients younger than 18 years at the time of biopsy who were diagnosed with LN or FHN. Specifically, patients having renal histology lesions compatible with LN by light microscopy and IF studies (i.e. positive complement staining and Ig glomerular depositions) were included. A few dubious cases that corresponded most likely to IgA/Henoch-Shönlein purpura nephropathy or membranoproliferative glomerulonephritis, with abundant deposition of immunoglobulins and complement factors, were excluded. No patients with positive ANCA antibodies were included in the study.
Follow-up schedules were variable among different centres; however, monthly data were available for most patients during the active phase of their diseases and every 3-6 months thereafter. If data were not available for >6 months, patient data were censored at the date of the last follow-up. Only patients for whom follow-up data were available for at least 6 months were included in the study.
Overall, 222 renal biopsies fulfilled the inclusion criteria; of these, 203 with sufficient follow-up data were finally included in the study.
Definitions SLE was diagnosed in all LN patients having at least three ACR criteria according to the revised 1997 definition [2] . 'Delayed SLE' (d-SLE) refers to those patients who did not have diagnostic criteria for SLE at onset, but developed one or more ACR criteria at 6 or more months after the disease onset; in all cases, patients developed antinuclear (with or without anti-DNA) antibody positivity, although they were negative at disease onset. All patients who had fewer than three criteria were defined as having FHN.
Renal pathology lesions were classified by the local pathologist according to the 1982 World Health Organization (WHO) classification. The IF pattern for IgG, IgM, IgA, C3 and C1q was graded on a 0-4+ scale.
Data collection and outcome evaluation
Medical records were reviewed to extract clinical information and laboratory values at the onset of disease and during follow-up. Nephrotic syndrome was defined as a proteinuria >3 g/day (>2 mg/mg creatinine in children unable to collect 24-h urine) and/or serum albumin levels <2.5 g/dL. Hypertension was defined as systolic and/or diastolic blood pressure above the 95th percentile for sex, age and height [14] .
Acute renal failure at onset was defined as an e-GFR < 90 mL/ min/1.73 m 2 in patients with a previously normal serum creatinine; the K/DOQI guidelines were used to define stages of chronic renal failure (CRF) [15] . GFR was estimated by the Schwartz formula (e-GFR) [16] .
Complete remission was defined as normal renal function and a proteinuria <0.5 g/day (or urinary protein/creatinine ratio <0.5 mg/mg) in at least two consecutive measurements on subsequent visits. Partial remission was defined as stable renal function and a reduction of proteinuria of at least 50% from baseline. Renal relapse was defined by an increase of >50% in proteinuria and/or by a decrease in e-GFR > 25% from baseline.
Treatment evaluation
As patients were collected in different centres over >20 years, treatment modalities varied significantly.
In general, most patients with WHO class II LN were treated with oral prednisone (PDN) that was rapidly tapered to low doses in association with azathioprine (AZA). Patients with class III and IV LN were generally treated with high-dose intravenous methylprednisolone pulses (MPP) followed by oral PDN that was gradually tapered to a maintenance dose. Until the mid-1990s patients with clinically severe disease received monthly intravenous cyclophosphamide (CYP) infusions for 6 months, then every 3 months for up to 24 months; lower doses, usually for 3-9 months were prescribed in more recent years. Some patients were treated with oral CYP. In the past 10 years, many patients were switched to or received mycophenolate mofetil (MMF) for maintenance therapy, in association with oral PDN; in a minority of cases, MMF was used as induction therapy. Finally, a minority of cases, generally with class V LN, were treated with cyclosporine A (CsA).
For the purpose of the analyses, the cumulative doses of MPP, of intravenous or oral CYP, the mean daily dose per kilogram of PDN, of AZA or CsA and the mean daily dose per square metre of MMF were recorded. Induction treatment was defined as the treatment taken during the first 6 months of disease. Maintenance treatment was calculated during the 12 months following induction therapy in 144 patients that had completed 18 months of follow-up.
Given the variability of treatment among patients, the following score was developed to measure treatment intensity without, however, intending to compare drug effectiveness: 
Outcome values were analysed with the Kaplan-Meier curve. Data were compared with the log-rank test. The impact of covariates was analysed with the Cox-Mantel test. Multivariate analysis was performed on covariates that reached the P < 0.1 threshold. All P-values are two-sided and considered significant for P < 0.05.
R E S U LT S

Patient characteristics
Among the 203 initially selected patients, 150 presented with SLE and 53 had FHN at onset. Among these latter patients, 11 (20.7%) developed other SLE symptoms on average after 5.0 years (range 0.6-14.3 years). These 11 patients were included in the study and were labelled, for the purpose of the analyses, as d-SLE. Thus, a total of 161 patients were studied.
Patient characteristics at the onset of nephropathy are reported in Table 1 . The mean follow-up was 96 months (range 6-296 months). Patients with SLE were on average older than those with d-SLE and had significantly lower complement levels. Overall, 32 patients (19.9%) had normal C3 levels and 38 patients (23.6%) had normal C4 levels. Female gender prevalence was present in both groups.
All patients diagnosed with SLE had at least three ACR criteria (range 3-8); all patients had ANA and/or anti-DNA antibody positivity at onset. Six d-SLE patients presented with isolated renal disease; one patient also had haemolytic anaemia, one patient thrombocytopenia, one patient arthritis, one patient neurological symptoms and one patient had a transiently positive antiphospholipid titre. During the followup, they also developed arthritis (n = 2), haemolytic anaemia and thrombocytopenia (n = 2), photosensitivity (n = 1), peripheral neuropathy (n = 1), deep vein thrombosis and pulmonary and cerebral haemorrhage (n = 1), seizures (n = 1), ANA (n = 9) and anti-DNA antibodies (n = 7). Table 2 summarizes renal pathology findings. Based on subsequent analyses showing lower probability of remission in class III and IV, histology lesions were further grouped into two classes ([class I + II + V] versus [class III + IV]) for comparison. As shown, the prevalence of proliferative lesions was 66.7% in patients with SLE and was significantly lower (36.4%) in the d-SLE group (P < 0.05). Equally, the IF was less intense in d-SLE biopsies compared with SLE samples, with the exception of IgM. Figure 1 shows the comparison of the treatment intensity score in the two groups of patients (detailed treatment doses are provided in Supplementary Table S1 ). d-SLE patients received significantly less medications for induction (mean score 1.02) compared with those with SLE (mean score 1.72, P < 0.02). Maintenance treatment was similar in all groups of patients.
Renal pathology
Treatment
Analysis of outcome
Survival curves are illustrated in Figure 2 . At 6 months, 70.1 and 30.8% of patients had achieved partial and complete remission, respectively. At 1 year, these numbers increased to 83.2 and 53.3% for partial and complete remission, respectively. After 3 years of follow-up, the proportion of patients in remission was 90.1% (for partial remission) and 80.1% (for complete remission) (Figure 2A and B) . Figure 2D and E illustrates the likelihood of developing CRF or ESRD. After 10 years, 21.4% of patients were projected to have reached CRF and 11.2% to have reached ESRD.
Relapse-free survival was calculated only in patients who had achieved at least partial remission and included only renal flares. As shown in Figure 3 , at 10 years more than half of the patients (54.6%) were projected to have relapsed. 
O R I G I N A L A R T I C L E L u p u s n e p h r i t i s i n c h i l d r e n a n d a d o l e s c e n t s
Evaluation of the analysis of covariates Predictors of outcome were analysed by Cox-Mantel regression. Tables 3 and 4 illustrate the analysis of the probability of entering partial remission and the risk of developing Stage III CRF.
By univariate analysis, partial remission was negatively associated with acute renal failure at presentation, hypertension at presentation, delayed development of SLE symptoms and with class IV LN. Patients with class V LN and patients who received more intense induction treatment were more likely to achieve partial remission. By multivariate analysis, the magnitude of the induction treatment was a positive prognostic factor for achieving partial remission (P = 0.012), whereas class IV LN was associated with a worst outcome (P = 0.045). Although borderline significant, younger age was another negative predictor of obtaining partial remission (P = 0.052).
The same analysis was performed to evaluate the predictors of Stage III CRF. Younger age was associated with a higher probability of developing CRF both in univariate (P = 0.0001) and in multivariate analysis (P = 0.003). In addition, d-SLE and class IV LN were significant risk factors for developing CRF (P = 0.014 and P = 0.042, respectively).
Additional analyses were performed to evaluate predictors of complete remission, of relapse and of ESRD and are provided in the online Supplementary Tables S2-S4 . By univariate analysis, the risk of relapse was positively associated with male gender. By multivariate analysis, complete remission was positively associated with a higher induction treatment (P = 0.014) and negatively associated with development of d-SLE (P = 0.004); the probability of ESRD was associated with the age at onset (P = 0.031).
D I S C U S S I O N
Currently, the diagnosis of SLE is based on a scoring system developed by the ACR [2] .
The presenting symptoms of SLE are frequently protean in paediatric patients [3] and many children begin the disease with a limited number of ACR criteria and may therefore not be diagnosed as having SLE after the first symptoms. Antinuclear antibodies are considered the hallmark of SLE [17] and are elevated in most paediatric patients; many children also present with hypocomplementemia, which is highly specific but not sensitive enough to constitute a criterion for diagnosis [18] . Moreover, the majority of paediatric SLE patients present with subclinical or overt renal involvement at the disease onset [1, 19] .
LN encompasses a characteristic set of lesions that have been classified in six separate histological classes by the WHO in 1982, subsequently revised in 1995 and 2004 [20] [21] [22] . Typically these lesions are characterized by extensive immune complex deposits and by complement deposition as revealed by IF studies.
The present study has limitations. It is a retrospective analysis and reading of renal biopsies was not centralized. Due to its multicentric nature and to the large period of time in which patients were collected, treatment varied widely between patients. Therefore, a treatment 'score' was developed with the sole purpose of evaluating treatment intensity in subgroups of patients, not of comparing treatment modalities. Finally, the analysis of relapses was restricted to renal involvement. Clearly, SLE is a multisystemic disease and both remission and relapses may involve other organs.
Despite this limitation, the present study represents one of the largest paediatric cohorts assembled to analyse mediumand long-term outcomes of LN that has been reported to date. During the past 10 years, smaller paediatric series have been reported from Egypt, Iran, India, Thailand, Korea, China, Taiwan, Serbia, Turkey, Europe and North America [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Most included patients with SLE, regardless of the presence of LN [23, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Comparison between these cohorts is difficult because of different inclusion criteria, definition of outcomes and racial distributions. Overall, previous data report male-to-female ratios ranging 1:2.8-1:15 and a prevalence of class IV LN, which F I G U R E 3 : Relapse-free survival. The outcome was only analysed on patients who have achieved at least partial remission. Only renal flares were included in the analysis. 
O R I G I N A L A R T I C L E
L u p u s n e p h r i t i s i n c h i l d r e n a n d a d o l e s c e n t s is generally the most frequently observed lesion, accounting for 23-88% of cases [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . When reported, 1-year partial and complete remission rates ranged 38-78% and 13-35%, respectively [23, 25, 26, 28-30, 32, 33, 35] , and the 5-year kidney survival was 77-97% [23, 24, [26] [27] [28] [29] [30] [31] [32] [33] 35] . Relapse rates after a mean follow-up of 3.1-8.3 years were 21-45% [23, 26, 28, 30, 35] . More recently, a retrospective analysis conducted by Pereira et al. [36] reported a progressive improvement in patient and kidney survival during the past three decades, mostly due to progress in treatment protocols and management of disease complications. Overall, the results of the Italian cohort are in line or are slightly better than those previously reported; this may be due in part to the inclusion of primarily Caucasian patients. Likewise, our data confirm that patients presenting with more severe renal disease at onset, in particular class IV LN, have a lower probability of achieving remission and a higher probability of developing CRF [23, 26, 27, 30-32, 34-35, 37] ; unlike some reports [23, 27] , however, we did not observe that male gender was associated with a poorer outcome. In addition, in our cohort patients with the delayed onset of SLE were included, thus allowing analysis of the probability of developing SLE symptoms over time.
A number of observations can be made based on the data that have been collected. First, approximately one-quarter of patients who have a histological diagnosis compatible with LN at onset do not meet criteria for the diagnosis of SLE; these patients are generally classified as having FHN or lupus sine lupus. Among these, approximately one-quarter will develop with time additional ACR criteria. Of note, however, most patients with FHN received treatment. Therefore, some may not have developed other SLE features because they were treated.
Patients with d-SLE presented with less severe renal lesions at onset (lower prevalence of proliferative lesions and weaker IF intensity staining with the exception of IgM). These are likely the main reasons for prescribing less intense induction treatment to these patients, which unfortunately led to a worse clinical response and worse long-term outcome. This observation highlights the importance of using equally intense induction regimens in all forms of LN in children in order to achieve a sustained remission. Obviously, this attitude may lead to over-treating some patients; however, poor prognosis of undertreated d-SLE patients favours, in our view, a more aggressive attitude. A recent case report series of four adult female patients with 'lupus-like nephritis' also suggests that these renal lesions may have a poor prognosis [8] . Finally, several reports have indicated in the past that younger children with SLE have a worse prognosis [37, 38] and our data clearly confirm this observation; these small children may need different treatment approaches than adolescent and adult patients.
CO N C L U S I O N
Taken together, the results of the Italian study indicate that LN has a worse prognosis in younger children and suggest that all patients with LN, regardless of the presence of other SLE symptoms, should be treated appropriately at the disease onset to achieve complete remission. 
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L U P U S N E P H R I T I S I N C H I L D R E N A N D A D O L E S C E N T S : R E S U LT S O F T H E I TA L I A N CO L L A B O R AT I V E S T U DY
NDT ERA-EDTA OLA has selected this publication for Blog commentary by its faculty in view of its quality and potential educational value. Rugierro and her colleagues report on behalf of the Italian Collaborative Study group the outcome of children and adolescents with Lupus Nephritis including those with delayed diagnosed SLE (d-SLE) whose renal biopsy was very suggestive of Lupus Nephritis in the initial absence of SLE diagnostic criteria including a negative lupus serology and normal complement levels. This comprehensive and long follow up retrospective analysis highlighted some risk factors associated with the progression of lupus nephritis, in this age group, as well as the fact that those with d-SLE and renal involvement (Full House Nephritis) have a reserved prognosis that warrants early intervention as this condition is children and adolescents is often associated with progression of CKD. This is consistent with similar observations made in the past by members of the same group that showed that more than 50% of such young patients with FHN progressed to significantly impaired kidney function in spite of immunosuppression (1).
The NDT ERA-EDTA OLA readers may be interested to learn more from the authors of this very interesting article about: (1) Other investigators labeled the FHN as Renal-Limited lupus-like glomerulonephritis (2) . This is based on the full house immune deposits features as well as the extraglomerular immune deposits along the tubular basement membrane (TBM) as well as the presence of endothelial Tubulo-Reticular inclusions (TRI). Did the patients followed-up in this study share some of these histological features?
(2) Some members of the Italian Collaborative Study group had recently suggested that the presence of immune deposits on skin immunofluorescence may distinguish those with primary FHN from those with FHN leading to delayed onset SLE (3) . Has this been applied to this study patients group? (3) As with previous publications, only a minority (25%) of children and adolescents with FHN went on to develop the diagnostic criteria of SLE. So why call this group d-SLE when the majority remains, in spite of the long follow-up (up to 10 years), outside the diagnostic criteria of this disease. A better name remains Full House Nephritis, rather than d-SLE or Renal-Limited SLE; after all they may never develop sufficient criteria to be labeled SLE. It seems as if the authors in this study decided to put all these patients under the same category?! (4) The presence of numerous classes and diffuse distribution of immune deposits clearly signifies a severe immune process that warrants careful evaluation and appropriate treatment. However, in this young age group, a careful Risk:Benefit analysis is still warranted before embarking on potentially dangerous immunosuppression, specially when unable to distinguish those who may go on to develop systemic or serological features of SLE compared to those with primary and isolated FHN.
Clearly, FHN is of poor prognosis but whether it is invariably a form of SLE is far from proven and consequently, whether it warrants the same therapeutic approach as the latter is also questionable.
